Loading data for CRDF — first visit, this takes a few seconds.

アラート

Cardiff Oncology Inc. (CRDF)

NasdaqCM: CRDF · リアルタイム株価 · USD

0.88

-0.03 (-3.30%)

終値時点： Aug 21, 2026, 8:00 PM

0.91

+3.06%

時間外: 7:44 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-3.30% (1D)

データがありません

買気配	0.65
時価総額	68.47M
売上高（TTM）	508K
純利益（TTM）	-40.08M
	1.44
	-0.6
	n/a
	-1.5
PBR（TTM）	2.27
PSR（TTM）	134.78
決算発表日	Nov 12, 2026

売気配	1.14
出来高	642,180
平均出来高（20日）	1,470,825
始値	0.92
前日終値	0.91
当日レンジ	0.88 - 0.93
52週レンジ	0.76 - 3.31
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

CRDFについて

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Jul 27, 2004

従業員数 30

上場取引所 NasdaqCM

ティッカー CRDF

ウェブサイト https://www.cardiffoncology.com

企業情報の全文

業績

2025年のCardiff Oncologyの売上高は593Kで、前年の683Kから-13.18%の減少でした。利益は-45.85Mで、0.92%の増加でした。

財務諸表

決算サプライズ

Cardiff OncologyはAug 11, 2026に四半期決算を発表しました：

売上高は $41K で、予想を下回りました $0, うち -62.39% の前年比減少.
EPSは -0.14 で、予想を上回りました 0.02, うち 33.33% の前年比増加にあたります.

次回決算発表

Cardiff Oncology Inc.の決算発表予定日は Nov 12, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1か月前 · InvestorsHub

Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital

Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncol...

1か月前 · Insider Monkey

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list. TheFly repor...

3か月前 · Simply Wall St.

Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist

Over the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stock...

5か月前 · MarketBeat

Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar

Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company’s investigational PLK1 inhibitor onvansertib during a webinar focused o...

5か月前 · MarketBeat

Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC

Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly se...

2ページ中1ページ

Cardiff Oncology Inc. (CRDF)